Navigating the Cancer Biomarkers Landscape: A Comprehensive Analysis of Key Players

-

The global cancer biomarkers market is projected to reach USD 28.2 billion by 2026 from USD 12.4 billion in 2021, at a CAGR of 17.7% during the forecast period. Growth in the cancer biomarkers market is mainly driven by factors such as the increasing use of cancer biomarkers in drug discovery & development and increasing R&D on cancer biomarkers. However, patent protection of cancer biomarkers and limited battery life are the major factors hampering the growth of this market.

The major players in this market are F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific, Inc. (US), QIAGEN N.V. (Netherlands), Illumina, Inc. (US), Bio-Rad Laboratories, Inc. (US), Abbott Laboratories (US), bioMérieux SA (US), Becton, Dickinson and Company (US), Merck Millipore (US), Agilent Technologies (US), Myriad Genetics, Inc. (US), Sysmex Corporation (Japan), Hologic, Inc. (US), Quest Diagnostics (US), Centogene N.V. (Germany), PerkinElmer, Inc.; (US), Siemens Healthineers (Germany), Exact Sciences (US), R&D Systems, Inc. (US), BioVision, Inc. (US), Olink (Sweden), Asuragen, Inc. (US), Meso Scale Diagnostics, LLC (US), Invivoscribe, Inc. (US), Seegene Technologies, Inc. (South Korea).

To know about the assumptions considered for the study download the pdf brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=202

F. Hoffmann-La Roche Ltd. held the leading position in the cancer biomarkers market in 2020. La Roche focuses on innovation to maintain its market share. It invests a significant amount of its revenue in R&D activities for this purpose. These investments are used to develop new and innovative products. The company’s major share comes from the US. With its high R&D capabilities, excellent balance sheet, and asset quality, the company is expected to witness a higher growth rate in the forecast period.

In 2020, Thermo Fisher Scientific, Inc. held the second position in the cancer biomarkers market. The company focuses on innovation to maintain its market share. It invests a significant amount of its revenue in R&D activities for this purpose. These investments are used to develop new and innovative products. The company’s major share comes from the US. With its high R&D capabilities, excellent balance sheet, and asset quality, the company is expected to witness a higher growth rate in the forecast period.

Qiagen N.V. held the leading position in the cancer biomarkers market in 2020. The company has a strong market presence globally, mainly due to its excellent customer network and delivery system. The company’s global footprint and the critical nature of its service portfolio play a key role in expanding access to healthcare in emerging and developed countries.

Opportunities: Personalized medicine

Personalized medicine identifies the most beneficial treatment path for individual patients. Cancer biomarkers play a very important role in certain aspects of personalized medicine. Consumables used in cancer biomarker testing enable the identification of these diseases. Cancer biomarker diagnostic products are also used as companion diagnostics for several investigational therapies. Thus, the field of personalized medicine is expected to offer potential growth opportunities for players operating in the cancer biomarkers market.

Drivers: Rising technological advancements In the development of cancer biomarkers

Array and proteomics technology advancements have addressed the challenges of identifying and understanding the functions and interactions of various proteins. These technological advancements have simplified the process of discovery and development of novel cancer biomarkers to a great extent.

Related Links

https://www.marketsandmarkets.com/Market-Reports/oncology-biomarkers-202.html

https://www.marketsandmarkets.com/PressReleases/oncology-biomarkers-market.asp

https://www.marketsandmarkets.com/ResearchInsight/oncology-biomarkers.asp

Comments

Post a Comment

Popular posts from this blog

Future of Remote Patient Monitoring Industry: Impact of Remote Patient Monitoring on Healthcare

-
Remote patient monitoring is a type of telemedicine technology that enables healthcare providers to monitor their patients’ health remotely. This technology utilizes remote devices that are placed in the patient’s home or worn by the patient to collect medical data such as vital signs and other medical information.  This medical data is then transmitted to the doctor or healthcare provider to help them make better decisions regarding the patient’s care. RPM can be used to monitor a variety of conditions including chronic diseases, mental health issues, and post-operative care. It can also be used to support elderly individuals and those with disabilities. RPM has the potential to improve patient outcomes and reduce healthcare costs by enabling healthcare providers to monitor their patients’ health more effectively. Benefits of Remote Patient Monitoring 1. Increased Patient Engagement: Remote patient monitoring systems provide patients with a convenient way to stay engaged in thei...
Read more

Strategies Adopted by the Major Players in this Digital PCR Market

-
 According to research report the  Digital PCR Market  is expected to grow from USD 3.47 billion in 2017 to USD 5.31 billion by 2022, at a CAGR of 8.9% during the forecast period. Product Launches: Key Strategy Adopted by the Major Players in this Market New product launches and approvals are the key growth strategies adopted by major players to strengthen their position in the global Digital PCR Market. Moreover, strategies such as partnerships, collaborations, and agreements; as well as mergers and acquisitions were also adopted by several market players to strengthen their market position, expand their R&D capabilities, and geographic presence in the global Digital PCR Market. The key players in the Digital PCR Market include Thermo Fisher Scientific, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (US), QIAGEN N.V. (Netherlands), Takara Bio, Inc. (Japan), Agilent Technologies, Inc. (US), bioMérieux S.A. (France), Fluid...
Read more

Sinus Dilation Devices Market Size And Share Report, 2027

-
The sinus dilation devices market is on track for significant growth in the coming years, projected to reach USD 3.8 billion by 2027, up from USD 2.8 billion in 2022. This represents a compound annual growth rate (CAGR) of 6.6% during the forecast period. The market's expansion is largely driven by the increasing availability of reimbursements and rising cases of chronic sinusitis. However, the market faces challenges due to the availability of non-surgical treatments for chronic sinusitis and a shortage of skilled ENT surgeons. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=64349810 Key Market Drivers Increasing Availability of Reimbursements: The growing availability of reimbursements for sinus dilation procedures is making them more accessible to patients, thereby driving demand for sinus dilation devices. Rising Incidence of Chronic Sinusitis: The prevalence of chronic sinusitis is on the rise globally, leading to an increase in d...
Read more